Sandoz legal costs weigh down profits

Published on August 5, 2026

by
Swissinfo
My articles My site About me My videos My books
Follow on:Twitter Facebook Google +

Swiss generic drugs giant Sandoz saw profits plummet by 70% in the first six months of the year as a result of huge legal costs. Profits slumped to $109 million after the company was fined around $480 million in the United States. The Rhine-based multinational had previously set aside provisions for this anticipated legal cost. The half-yearly report published on Wednesday also lists restructuring costs of $54 million, costs relating to empowerment of $47 million, costs for optimising production facilities of $41 million and software deployment costs of $33 million. Turnover grew by 10% in US dollars, or 5% in local currencies, to $5.76 billion. This performance was driven in particular by a 25% rise in revenue from biosimilars, to $1.86 billion. Revenue from the core generics business stabilised, falling by 1% in local currencies but rising by 4% when converted into US dollars, to $3.89 billion. Attributed to disruptions in the penicillin market, the decline stood at 3% over the ... Full story here Are you the author?

About Swissinfo

SWI swissinfo.ch – the international service of the Swiss Broadcasting Corporation (SBC). Since 1999, swissinfo.ch has fulfilled the federal government’s mandate to distribute information about Switzerland internationally, supplementing the online offerings of the radio and television stations of the SBC. Today, the international service is directed above all at an international audience interested in Switzerland, as well as at Swiss citizens living abroad.

My articles My site About me My books
Follow on:Twitter Facebook Google +